Recalls by Dr Reddy's, Torrent Put Spotlight on Quality Standards in India's Semaglutide Market Written By Farhat Nasim10 July 2026 5:28 PM ISTNew Delhi: Three Indian pharmaceutical companies, Dr. Reddy's Laboratories, Torrent Pharmaceuticals and USV, have initiated voluntary recalls of...
Medical Bulletin 27/June/2026 Written By Anshika Mishra27 Jun 2026 3:00 PM ISTHere are the top medical news for today:New Trial Establishes Safe Daily L-Tyrosine Intake for Healthy Adults A four-week course of L-tyrosine...
GLP-1 Weight Loss Drugs Linked to Reduced Risk of Violent Behavior: Study Written By Anshika Mishra27 Jun 2026 8:15 AM ISTA class of medications commonly prescribed for diabetes and weight management may be linked to reduced violent behavior by weakening the connection...
Eli Lilly Targets Europe Launch of Weight-Loss Pill by Early 2027, Bets on Telehealth Market Written By sheeba farhat24 Jun 2026 11:15 AM ISTBrussels: Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker...
Bariatric Surgery Outperforms GLP-1 Drugs for Weight Loss, Disease Remission, finds study Written By Dr. Kamal Kant Kohli19 May 2026 8:45 PM ISTMetabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like...
Eli Lilly to Ink USD 2 Billion AI Drug Deal with Insilico for GLP-1 Diabetes Therapy Written By sheeba farhat30 March 2026 11:00 AM ISTBengaluru: U.S. drugmaker Eli Lilly will sign a USD 2 billion deal with Hong Kong-listed biotech Insilico Medicine, which uses artificial...
Hetero Launches Generic Semaglutide Brands Truglyx, Rolmodl, Moto G Across 75+ Countries Written By sheeba farhat28 March 2026 8:22 PM ISTNew Delhi: Hetero has announced the export launch of its generic semaglutide portfolio, marking a significant step toward expanding access to GLP-1...
Semaglutide Patent Expiry Sparks Generic Rush in India, Prices Set to Drop Sharply Written By sheeba farhat20 March 2026 11:13 PM ISTHyderabad: India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires...
Biocon Gets USFDA Nod for gSaxenda, Enters US GLP-1 Weight Loss Market Written By sheeba farhat25 Feb 2026 2:55 PM ISTNew Delhi: Biocon Limited has secured approval from the U.S. Food and Drug Administration (USFDA) for its complex formulation Liraglutide Injection,...
Novo Nordisk Loses USD 50 Billion as Obesity Drug Price War Triggers Profit, Sales Warning Written By sheeba farhat6 Feb 2026 11:15 AM ISTNew Delhi: Novo Nordisk's shares tumbled on Wednesday, knocking nearly USD 50 billion in value from the Danish obesity drug giant, as it warned that...
SURPASS-2- Tirzepatide vs Semaglutide in Type 2 Diabetes Written By Deeksha Bhandari4 Feb 2026 12:30 PM ISTKey Summary: In addition to meeting the primary objective of noninferiority to semaglutide in type 2 diabetes (T2D), tirzepatide, at a dose of...
Natco Pharma Challenges Novo Nordisk's Wegovy Patent, Reaches Delhi High Court Written By Susmita Roy7 Jan 2026 11:19 PM ISTNew Delhi: Hyderabad-based Natco Pharma has approached the Delhi High Court with a petition seeking revocation of a patent held by Novo Nordisk, the...
